Levosimendan Waymade: Uses, Dosage & Side Effects

What Is Levosimendan Waymade and What Is It Used For?

Levosimendan Waymade contains the active substance levosimendan, a calcium sensitizer belonging to the pyridazinone-dinitrile chemical class. It represents a fundamentally different approach to treating acute heart failure compared with traditional inotropic agents. While conventional inotropes such as dobutamine (a beta-adrenergic agonist) and milrinone (a phosphodiesterase III inhibitor) increase cardiac contractility primarily by raising intracellular calcium concentrations, levosimendan enhances contractility by making the heart muscle more sensitive to the calcium that is already present. This distinction is clinically important because elevated intracellular calcium levels are associated with increased myocardial oxygen consumption, arrhythmogenicity, and potential cell damage—problems that are largely avoided with levosimendan's calcium-sensitizing mechanism.

The mechanism of action of levosimendan involves three distinct pharmacological pathways that together define its unique therapeutic profile. First, levosimendan binds to cardiac troponin C (cTnC) in a calcium-dependent manner, stabilizing the calcium-troponin C interaction and enhancing the responsiveness of the contractile machinery to calcium ions. This binding occurs selectively during systole (when calcium concentrations are elevated) and dissociates during diastole (when calcium levels fall), thereby improving systolic contraction without impairing diastolic relaxation. This is a crucial advantage because impaired diastolic relaxation is a significant clinical problem in heart failure, and traditional inotropes can worsen this condition. Second, levosimendan opens ATP-sensitive potassium channels (K_ATP) in vascular smooth muscle cells, causing relaxation of both arterial and venous smooth muscle. This results in vasodilation, reducing both preload (the volume of blood returning to the heart) and afterload (the resistance against which the heart must pump), thereby decreasing the workload on the failing heart while improving tissue perfusion. Third, levosimendan opens mitochondrial K_ATP channels in cardiomyocytes, which is believed to provide cardioprotective effects, including protection against ischemia-reperfusion injury and reduced apoptosis (programmed cell death) of heart muscle cells.

Levosimendan Waymade is indicated for the short-term treatment of acutely decompensated severe chronic heart failure in situations where conventional therapy (such as diuretics, angiotensin-converting enzyme inhibitors, and cardiac glycosides like digoxin) is not sufficient and where inotropic support is considered necessary. This typically occurs in patients with New York Heart Association (NYHA) functional class III or IV heart failure who present with acute worsening of symptoms, including severe dyspnea (shortness of breath) at rest, fluid overload unresponsive to diuretic therapy, and evidence of reduced cardiac output with organ hypoperfusion (such as reduced urine output, cool extremities, altered mental status, or elevated serum lactate levels).

The clinical evidence supporting levosimendan's efficacy in acute heart failure comes from several landmark randomized controlled trials. The LIDO (Levosimendan Infusion versus Dobutamine) trial compared levosimendan to dobutamine in 203 patients with severe low-output heart failure and demonstrated that levosimendan produced significantly greater hemodynamic improvement (defined as an increase in cardiac output of at least 30% together with a decrease in pulmonary capillary wedge pressure of at least 25%) compared with dobutamine. The RUSSLAN trial evaluated levosimendan in patients with acute heart failure complicating myocardial infarction and showed that levosimendan reduced the risk of death and worsening heart failure. The SURVIVE trial, the largest study of levosimendan to date, compared levosimendan with dobutamine in 1,327 patients hospitalized for acute heart failure requiring inotropic support. While the primary endpoint of 180-day all-cause mortality did not reach statistical significance, levosimendan was associated with a more rapid and sustained reduction in B-type natriuretic peptide (BNP) levels, a biomarker of heart failure severity, and a lower initial mortality at 5 days.

One of the most distinctive pharmacological features of levosimendan is the formation of an active metabolite known as OR-1896. Levosimendan itself has a relatively short elimination half-life of approximately 1 hour. However, it is metabolized in the body through two principal pathways. The first involves conjugation with glutathione to form inactive metabolites. The second involves reduction of the amino group to form an intermediate metabolite (OR-1855) that is subsequently acetylated to form OR-1896. This active metabolite has a half-life of approximately 75–80 hours and possesses calcium-sensitizing and vasodilating properties similar to the parent compound. As a result, the hemodynamic effects of a single 24-hour infusion of levosimendan can persist for 7 to 9 days after the infusion is discontinued. This prolonged duration of action is a significant clinical advantage, as it provides sustained hemodynamic support during the critical recovery period following an acute heart failure episode without the need for continued intravenous infusion.

What Should You Know Before Receiving Levosimendan Waymade?

Contraindications

Levosimendan Waymade is contraindicated in several clinical situations where its administration could be harmful or where the risks clearly outweigh any potential benefits. Understanding these contraindications is essential for the safe use of this medication. The primary contraindication is hypersensitivity (allergy) to levosimendan or to any of the excipients in the formulation. The concentrate for solution for infusion contains ethanol and povidone, among other inactive ingredients, and patients with known allergies to these substances should not receive the drug.

Levosimendan must not be given to patients with significant hypotension and tachycardia. Specifically, it is contraindicated in patients with a systolic blood pressure below 85 mmHg or a heart rate exceeding 120 beats per minute, as the vasodilatory effects of levosimendan could further reduce blood pressure to dangerously low levels while the heart rate may increase further, potentially compromising coronary perfusion and cardiac function. Patients with mechanical obstructions that affect ventricular filling or outflow—such as severe aortic or mitral stenosis, hypertrophic obstructive cardiomyopathy, or cardiac tamponade—must not receive levosimendan, as inotropic and vasodilatory effects would not address the underlying mechanical problem and could exacerbate hemodynamic instability.

Severe renal impairment (creatinine clearance less than 30 ml/min) and severe hepatic impairment are additional contraindications. The active metabolite OR-1896 depends on adequate renal function for elimination, and accumulation in patients with severe renal dysfunction could lead to prolonged and unpredictable hemodynamic effects. Similarly, patients with severe liver disease may have altered metabolism of levosimendan, affecting both the rate of formation of the active metabolite and its clearance. A history of torsades de pointes, a specific type of potentially fatal ventricular arrhythmia, is also a contraindication because levosimendan may prolong the QT interval in some patients and could theoretically increase the risk of recurrence of this arrhythmia.

Warnings and Precautions

Several clinical situations require special caution when using levosimendan. In patients with mild to moderate hypotension (systolic blood pressure 85–100 mmHg), the optional loading dose should be omitted, and the infusion should be commenced at the lowest recommended rate (0.05 mcg/kg/min) with careful upward titration guided by hemodynamic response. Blood pressure should be monitored frequently—ideally continuously via an arterial line—and the infusion rate reduced or discontinued if clinically significant hypotension develops.

Patients with mild to moderate renal impairment and those with mild to moderate hepatic impairment require careful dose adjustment and extended monitoring. Although formal pharmacokinetic studies in these populations have shown only modest alterations in drug disposition, the clinical effects may be prolonged due to altered metabolism and clearance of the active metabolite. Monitoring should be extended beyond the usual 3-day period in these patients, potentially up to 5–7 days post-infusion.

Electrolyte abnormalities, particularly hypokalemia (low potassium levels), must be corrected before starting levosimendan and monitored throughout the infusion. Hypokalemia increases the sensitivity of the myocardium to arrhythmias and can enhance the QT-prolonging potential of levosimendan. Serum potassium levels should be maintained within the normal range (3.5–5.0 mmol/L) throughout treatment. Concurrent diuretic therapy, commonly used in heart failure patients, can exacerbate potassium losses and should be monitored carefully.

In patients with coronary artery disease and acute coronary syndromes, levosimendan should be used with caution. While its mechanism of action is not expected to increase myocardial oxygen demand (unlike traditional inotropes), the vasodilatory effects can potentially lead to coronary steal phenomenon in some patients. The drug should be used in these patients only when the benefits of inotropic support clearly outweigh the potential risks, and close monitoring of ECG for signs of ischemia is recommended.

Patients receiving concomitant intravenous vasodilators, antihypertensive agents, or other inotropes are at increased risk of hypotension. The combination of levosimendan with other inotropes or vasodilators should be used with caution, and patients should have invasive hemodynamic monitoring (such as a pulmonary artery catheter) when multiple vasoactive agents are being administered concurrently. Heart rate should be monitored carefully, as levosimendan can cause a reflex tachycardia secondary to vasodilation, and patients with atrial fibrillation may experience an increase in ventricular rate.

Pregnancy and Breastfeeding

The safety of levosimendan during pregnancy has not been established in humans. Animal reproduction studies have shown some adverse effects at doses substantially above the therapeutic range in humans, including decreased fetal weight and delayed ossification. As the drug is used in life-threatening situations (acute decompensated heart failure), the decision to use levosimendan during pregnancy should be made on a case-by-case basis by the treating physician, weighing the potential risk to the fetus against the critical need for inotropic support in the mother. Adequate contraception should be used by women of childbearing potential during and after treatment, considering the prolonged activity of the active metabolite.

It is not known whether levosimendan or its metabolites are excreted in human breast milk. Given the severity of the condition being treated and the hospital setting in which the drug is administered, breastfeeding during and for at least 14 days after treatment (to account for the long half-life of the active metabolite OR-1896) should be discussed with the treating physician. In most cases, the clinical situation of a mother requiring intravenous inotropic support will preclude breastfeeding during the acute treatment phase.

Elderly Patients

Clinical trials with levosimendan have included a significant proportion of elderly patients, and no overall differences in safety or efficacy have been observed between older and younger patients. However, elderly patients are more likely to have reduced renal and hepatic function, which may affect the metabolism and elimination of levosimendan and its active metabolite. More frequent monitoring and potentially longer post-infusion observation periods may be warranted in patients over 75 years of age. Additionally, elderly patients may be more susceptible to the hypotensive effects of levosimendan due to reduced baroreceptor sensitivity and concurrent use of multiple antihypertensive medications.

How Does Levosimendan Waymade Interact with Other Drugs?

Understanding drug interactions is critical when administering levosimendan, as patients with acute decompensated heart failure are typically receiving multiple concurrent medications. Levosimendan is highly protein-bound (97–98% to plasma albumin) but is not metabolized by cytochrome P450 enzymes to any significant degree. Instead, it is metabolized primarily through glutathione conjugation and reduction. This means that traditional CYP450-mediated drug interactions are unlikely. However, several pharmacodynamic interactions (where two drugs have additive or opposing effects on the same physiological system) are clinically important.

The most significant interaction is with other vasodilators and antihypertensive agents. Co-administration of levosimendan with isosorbide mononitrate in healthy volunteers resulted in a significant enhancement of the orthostatic hypotensive response (postural drop in blood pressure). This additive hypotensive effect is expected with all vasodilators, including nitrates (nitroglycerin, isosorbide dinitrate), sodium nitroprusside, hydralazine, and nesiritide. Patients receiving these agents concurrently with levosimendan require particularly close blood pressure monitoring and may need dose reductions of one or both agents.

Formal pharmacokinetic interaction studies have been conducted with several medications commonly used in heart failure patients, and no clinically significant interactions were found. Specifically, levosimendan does not alter the pharmacokinetics of digoxin at steady state, and digoxin does not affect the pharmacokinetics of levosimendan. Similarly, no clinically relevant interaction was observed between levosimendan and warfarin (with no changes in INR or warfarin pharmacokinetics), or between levosimendan and carvedilol (a commonly used beta-blocker in heart failure). The combination of levosimendan with beta-blockers did not reduce the hemodynamic effects of levosimendan in clinical studies, suggesting that beta-blocker therapy does not need to be discontinued before levosimendan administration.

Major Interactions

The combination of levosimendan with intravenous nitrates or sodium nitroprusside carries the highest risk of clinically significant hypotension. In the pivotal clinical trials, concurrent use of intravenous vasodilators was associated with a higher incidence of hypotension requiring dose adjustment or temporary cessation of the levosimendan infusion. When both agents are deemed necessary, they should be titrated independently with continuous arterial blood pressure monitoring, and the clinician should be prepared to rapidly reduce or stop one or both infusions if significant hypotension occurs.

The use of levosimendan in combination with or immediately following other intravenous inotropic agents (such as dobutamine or milrinone) requires particular caution. While these combinations may be necessary in patients with refractory cardiogenic shock, the additive inotropic and vasodilatory effects increase the risk of hypotension, tachycardia, and cardiac arrhythmias. Pulmonary artery catheter monitoring is recommended when such combinations are employed, allowing direct measurement of cardiac output, pulmonary artery pressures, and systemic vascular resistance to guide dosing decisions.

Minor Interactions

The interaction between levosimendan and loop diuretics (furosemide, bumetanide) is primarily related to their shared tendency to cause hypokalemia and volume depletion. While not a direct pharmacological interaction, the concurrent use of high-dose loop diuretics and levosimendan may increase the risk of hypotension and electrolyte disturbances. Regular monitoring of serum potassium, magnesium, and fluid balance is essential. Oral medications commonly used in chronic heart failure management, including ACE inhibitors, angiotensin receptor blockers, and beta-blockers, can generally be continued during levosimendan infusion, although blood pressure should be monitored more frequently during the infusion period.

What Is the Correct Dosage of Levosimendan Waymade?

Levosimendan Waymade is supplied as a 2.5 mg/ml concentrate for solution for infusion that must be diluted before administration. The concentrate is typically diluted to a final concentration of 0.025 mg/ml using 5% dextrose (glucose) solution. A 5 ml vial (containing 12.5 mg levosimendan) is diluted with 500 ml of 5% dextrose to achieve this concentration. The diluted solution should be a clear yellow to orange solution, and any solutions showing particulate matter or discoloration should be discarded. The preparation should be performed using aseptic technique, and the diluted solution should be used within 24 hours.

Adults

The hemodynamic effects of levosimendan typically become apparent within 5 minutes of initiating the loading dose and are fully established within 10–20 minutes. With the maintenance infusion alone (without loading dose), hemodynamic effects develop more gradually over the first 1–2 hours. Peak effects of the infusion are typically observed after 6–8 hours of continuous administration.

Children

Levosimendan Waymade is not approved for use in children and adolescents under 18 years of age. The safety and efficacy of levosimendan in the pediatric population have not been established through adequate and well-controlled clinical trials. While limited published case series and observational studies have described off-label use of levosimendan in pediatric patients with various forms of heart failure and after cardiac surgery, the evidence base is insufficient to provide reliable dosing recommendations. Pediatric patients with acute heart failure should be managed according to age-specific guidelines by pediatric cardiology specialists.

Elderly

No specific dose adjustment is required based solely on age. However, as elderly patients are more likely to have impaired renal and hepatic function, concurrent medications that lower blood pressure, and reduced physiological reserve, a more conservative dosing approach is generally recommended. Starting with the lower loading dose (6 mcg/kg) or omitting the loading dose entirely, and initiating the maintenance infusion at 0.05 mcg/kg/min with gradual upward titration, is a prudent approach in patients over 75 years of age. The post-infusion monitoring period should be extended in elderly patients to account for potentially prolonged effects of the active metabolite.

Repeated Administration

Because levosimendan is administered as a single continuous infusion in a hospital setting, the concept of a "missed dose" does not apply in the traditional sense. If the infusion is inadvertently interrupted, it can be restarted; however, the decision to administer a repeat loading dose should be based on clinical assessment and hemodynamic status. Repeated infusions of levosimendan have been studied in patients with advanced chronic heart failure who experience recurrent decompensation episodes. Limited evidence from studies such as the LION-HEART trial suggests that intermittent levosimendan infusions (typically every 2–4 weeks) may improve hemodynamics, reduce natriuretic peptide levels, and improve quality of life in patients with advanced heart failure. However, this "pulsed" or "repetitive" use is not universally approved and should be considered only in specialized heart failure centers.

Overdose

Overdose with levosimendan would be expected to produce exaggerated pharmacological effects, principally severe hypotension and tachycardia. At very high doses, QT prolongation and ventricular arrhythmias (including torsades de pointes) could occur. There is no specific antidote for levosimendan overdose. Management is supportive and should be guided by hemodynamic monitoring. Hypotension should be treated with intravenous fluid administration and, if necessary, vasopressor agents such as norepinephrine or vasopressin. Tachyarrhythmias should be treated according to standard protocols. It is important to remember that the effects of levosimendan overdose may be prolonged for several days due to the active metabolite OR-1896, and patients should be monitored in an intensive care setting for an extended period.

What Are the Side Effects of Levosimendan Waymade?

Like all medicines, Levosimendan Waymade can cause side effects, although not everyone experiences them. The side effect profile of levosimendan is largely a consequence of its pharmacological actions: vasodilation leading to hypotension and reflex tachycardia, and cardiac electrophysiological effects contributing to arrhythmias. Many of these effects are dose-dependent and can be managed by adjusting the infusion rate. It is important to recognize that the patients receiving levosimendan have severe heart failure and are often critically ill, making it challenging to distinguish drug-related adverse effects from the natural progression of the underlying disease.

The following frequency classification is used: very common (affects more than 1 in 10 patients), common (affects 1 in 10 to 1 in 100 patients), uncommon (affects 1 in 100 to 1 in 1,000 patients), and rare (affects fewer than 1 in 1,000 patients). The frequencies reported here are based on data from controlled clinical trials and post-marketing surveillance.

Hypotension is the most clinically significant side effect and is directly related to the vasodilatory action of levosimendan. The incidence and severity of hypotension are dose-dependent, with higher loading doses and faster infusion rates associated with more pronounced blood pressure reduction. In the SURVIVE trial, hypotension requiring intervention occurred in approximately 50% of patients in the levosimendan group compared with 36% in the dobutamine group. Hypotension can usually be managed by reducing the infusion rate, administering intravenous fluids, or temporarily interrupting the infusion. In severe cases, vasopressor support may be necessary.

Cardiac arrhythmias are common during levosimendan therapy, reflecting both the pharmacological effects of the drug and the high baseline arrhythmia risk in patients with severe heart failure. Ventricular tachycardia was observed in 12–15% of patients in clinical trials, although the majority of episodes were non-sustained and hemodynamically tolerated. Atrial fibrillation, either new-onset or worsening of pre-existing atrial fibrillation, occurred in approximately 6–9% of patients. These arrhythmias are more common in patients with pre-existing arrhythmia substrates, electrolyte abnormalities (particularly hypokalemia and hypomagnesemia), and those receiving concomitant medications that affect cardiac electrophysiology.

Hypokalemia is commonly observed during and after levosimendan infusion, occurring in approximately 5–8% of patients. This is partly related to the vasodilatory effect (activation of the renin-angiotensin-aldosterone system leading to renal potassium losses), concurrent diuretic therapy, and the direct effects of potassium channel opening. Potassium levels should be monitored regularly and supplemented as needed to maintain serum levels above 4.0 mmol/L, particularly in patients receiving digoxin or antiarrhythmic drugs.

Headache, occurring in approximately 10–15% of patients, is thought to be related to the vasodilatory effects of levosimendan on cerebral blood vessels, similar to the headaches caused by nitrate therapy. This effect is generally mild and self-limiting. Gastrointestinal symptoms (nausea, vomiting, constipation, diarrhea) each occur in approximately 3–5% of patients and are generally mild.

How Should You Store Levosimendan Waymade?

Proper storage of Levosimendan Waymade is essential to maintain its stability and efficacy. The concentrate for solution for infusion (2.5 mg/ml) is a clear yellow to orange solution supplied in amber glass vials. The color of the solution may vary within the yellow-to-orange range, and this variation is normal and does not indicate degradation. However, any solution that appears cloudy, contains visible particles, or has changed color significantly from the expected range should not be used.

Unopened vials should be stored in a refrigerator at 2–8°C (36–46°F). The vials must be kept in the outer carton to protect from light, as levosimendan is sensitive to light degradation. The concentrate must not be frozen. Before use, the vials should be allowed to reach room temperature. Levosimendan Waymade should not be used after the expiry date stated on the vial label and carton. The expiry date refers to the last day of that month.

Once diluted for infusion (typically with 5% dextrose solution), the diluted solution has been shown to be chemically and physically stable for 24 hours at 25°C (77°F). From a microbiological perspective, the diluted solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not exceed 24 hours at 15–25°C. The diluted solution should also be protected from light during the infusion, although standard infusion line tubing provides some protection. Any remaining diluted solution after the infusion period should be discarded.

Do not dispose of levosimendan or any unused diluted solution via household waste or wastewater. All unused medicinal product or waste material should be disposed of in accordance with local hospital protocols for pharmaceutical waste disposal. Healthcare professionals should follow institutional guidelines for handling and disposing of chemotherapeutic and pharmacological waste.

What Does Levosimendan Waymade Contain?

Levosimendan Waymade is supplied as a concentrate for solution for infusion. Understanding its composition is important for healthcare professionals to ensure appropriate dilution, storage, and administration, and to identify any potential allergies or sensitivities to the inactive ingredients.

Active substance: Each ml of concentrate contains 2.5 mg of levosimendan. Each 5 ml vial contains 12.5 mg of levosimendan. Levosimendan is a pyridazinone-dinitrile derivative with the chemical name (R)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile. It is a yellow to orange crystalline powder that is practically insoluble in water, which is why ethanol is used as a solvent in the concentrate.

Excipients (inactive ingredients):

• Povidone: A water-soluble polymer used as a stabilizer and viscosity-enhancing agent in the formulation.
• Citric acid: Used as a buffering agent to maintain the pH of the solution within the optimal range for stability.
• Ethanol (absolute): Used as the primary solvent because levosimendan has very low water solubility. The concentrate contains approximately 98% v/v ethanol. When diluted as directed (e.g., 5 ml in 500 ml of 5% dextrose), the final ethanol concentration in the infusion solution is less than 1% and is not clinically significant. However, the ethanol content should be taken into consideration in pregnant or breastfeeding women, in patients with liver disease or epilepsy, and in patients with alcohol dependence.
• Water for injections: Used as a co-solvent in the concentrate.

The concentrated solution appears as a clear yellow to orange liquid. After dilution in 5% dextrose solution, the infusion fluid should appear as a clear yellow solution. The concentrate does not contain any preservatives, antimicrobial agents, or antioxidants. It does not contain sugar, lactose, gluten, or latex. The formulation is free from human or animal-derived proteins.

Frequently Asked Questions About Levosimendan Waymade